An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors

Trial Profile

An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs M 8891 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 04 Jul 2017 Planned End Date changed from 2 Aug 2018 to 18 Jan 2019.
    • 04 Jul 2017 Planned primary completion date changed from 2 May 2018 to 18 Jan 2019.
    • 04 Jul 2017 Planned initiation date changed from 12 May 2017 to 24 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top